Best of ASCO 2025 | Hybrid Event in Greece

62
Speakers
2
Days
127
Registrations
15
Sponsors
Τα πιστοποιητικά είναι διαθέσιμα!
Δεν υπάρχουν διαθέσιμα δεδομένα. Επικοινωνήστε μαζί μας μέσω email ζητώντας την πιστοποίησή σας ή καλέστε μας για να σας βοηθήσουμε.

Chairs: N. Tsoukalas, D. Papageorgiou

12.00-12.20 Presenter: M. Lavdaniti

Abstract 11001: Outcomes of an electronic patient-reported outcomes (ePRO) - based symptom management program (eSyM): A cluster randomized trial.

Abstract 11003: Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment.

12.20-12.40 Presenter: C. Ntola

Abstract 12006: A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors

Abstract 12007: Romiplostim for chemotherapyinduced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).

12.40-13.00 Discussants: Ν. Tsoukalas, D. Papageorgiou

13.00-14.10 Session 2 | Head and Neck Cancer (HNC)

Chairs: A. Kotsakis, V. Lachanas

13.00-13.30 Presenter: P. Katsaounis

Abstract 6012: Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.

Abstract LBA2: NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Abstract LBA6003: PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.

13.30-13.50 Presenter: E. Chantzara

Abstract 6001: Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).

Abstract 6008: Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial.

13.50-14.10 Discussant: A. Psyrri

Chairs: C. Kosmas, C. Panopoulos
Presenter: A. Stribakos
Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations

Chairs: G. Rigakos, S. Labropoulos

15.40-16.00 Presenter: D. Kalapanida

Abstract 2011: Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.

Abstract 2002: Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.

16.00-16.20 Discussant: G. Rigakos

Chairs: A. Psyrri, P. Katsaounis

16.20-16.50 Presenter: G. Karkaletsos

Abstract 3002: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).

Abstract 3001: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.

Abstract 3004: Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.

16.50-17.10 Presenter: A. Lazarou

Abstract 2501: First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.

Abstract 2513: Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.

17.10-17.30 Presenter: S. Kokkali

Abstract 3007: Ultra-sensitive pan-cancer molecular residual disease molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.

Abstract 3006: Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.

17.30-17.40 Discussant E. Kontopodis

Chairs: A. Koutras, I. Kotteas

18.00-18.20 Presenter: K. Rapti

Abstract 505: 15-year outcomes for women with premenopausal hormone
receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.

Abstract 507: The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.

18.20-18.40 Presenter: A. Kokkalis
Abstract LBA500: De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.

Abstract 501: Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/ Compass HER2 pCR trial.

18.40-19.00 Discussant A. Nikolaidi

Chairs: V. Barbounis, E. Galani

19.00-19.20 Presenter: C. Aidarinis

Abstract LBA1000: Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.

Abstract LBA4: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

19.20-19.40 Presenter: N. Asimakopoulou

Abstract LBA109: Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.

Abstract LBA1008: Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09.

19.40- 20.00 Discussant E. Saloustros

Chairs: A. Stribakos, I. Samaras

09.00-09.40 Presenter: Μ. Avgoustidou

Abstract LBA3500: First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses.
Abstract 3505: Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).

Abstract 3501: Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.

Abstract LBA1: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).

09.40-10.00 Discussant: G. Oikonomopoulos

Chairs: P. Papakostas, Μ. Theochari

10.00-10.20 Presenter: M. Drizou

Abstract LBA5: Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

Abstract 4000: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.

10.20-10.40 Presenter: A. Markou

Abstract LBA4002: Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized,
phase 3 DESTINY-Gastric04 study.

Abstract LBA4005: PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

10.40-11.00 Discussant G. Papaxoinis

Chairs: C. Kosmas, G. Sotiropoulos

Presenter: N. Machairas

Liver Transplantation in Metastatic Cancer

Discussion

Chairs: D. Bafaloukos, A. Tzovaras

12.00-12.20 Presenter: A. Laskarakis

Abstract LBA9507: A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).

Abstract 9506: DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM) - Final clinical results.

12.20-12.50 Presenter: I. Gazouli

Abstract LBA9508: Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first line treatment for metastatic melanoma: Results of the DANTE phase III trial.

Abstract LBA9500: Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.

Abstract 9515: Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.

12.50-13.00 Discussant D. Ziogas

Chairs: M. Nikolaou, E. Saloustros

13.00-13.30 Presenter: S. Goura

Abstract 10509: Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.

Abstract 10510: Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer.

Abstract 10500: Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.

13.30-13.40 Panel Discussion

Chairs: C. Papadimitriou, M. Liontos

14.30-14.50 Presenter: E. Eleftherakis-Papaiakovou

Abstract LBA5500: TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).

Abstract 5511: Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.

14.50-15.00 Presenter: E. Chantzara

Abstract LBA5504: Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

15.00-15.20 Discussant: M. Rovithi

Chairs: A. Koumarianou, A. Boutis

15.20-15.40 Presenter: E.-G. Fergadis

Abstract 8006: Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.

Abstract LBA8008: Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial.

15.40-15.50 Presenter: A. Pantazopoulos

Abstract 8001: Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.

15.50-16.10 Discussant: A. Grivas

Chairs: A. Kotsakis, A. Charpidou

16.10-16.30 Presenter: S. Chrysoglou

Abstract 8506: Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

Abstract LBA8505: Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

16.30-16.50 Presenter: G. Christodoulopoulos

Abstract LBA8000: Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

Abstract 8500: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

16.50-17.10 Discussant: G. Evangelou

Chairs: M. Tsiatas, I. Kotsantis

17.30-17.50 Presenter: T. Tegos

Abstract LBA500 acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.

Abstract 5001: Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.

17.50-18.10 Presenter: E. Christakou

Abstract 4505: Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.

Abstract 4514: Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).

18.10-18.40 Presenter: N. Cholis

Abstract 4500: Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.

Abstract 4503: Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

Abstract 4517: Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.

18.40-19.00 Discussant: E. Lianos

Aidarinis V.
Resident of Medical Oncology University Hospital of Larissa
Ardavanis – Loukeris G.
Resident of Οncology, Saint Savvas General Anticancer Oncological Hospital of Athens
Asimakopoulou N.
MD, PhD, Medical Oncologist, 1st Oncology Dpt, Metropolitan General, Athens, Greece
Avgoustidou M.
MD, ehem.OÄ, FÄ, German Board certified Oncologist / Hematologist Specialized in Palliative Care, Athens Medical Group, Athens, Greece
Bafaloukos D.
Medical Oncologist, Director A’ Oncology Dpt., Metropolitan Hospital of Athens, Professor em. - University of W. Attica, Greece
Barbounis V.
Medical Oncologist, Director, 5th Oncology Clinic, IASO Hospital, Athens, Greece
Boutis A.
Consultant Medical Oncologist, Director, 3rd Med. Oncology Dept., “Theagenio” Anticancer Hospital of Thessaloniki, Greece
Charpidou A.
MD, PhD, FCCP, Pulmonologist, Professor (Assoc) Medical Oncology, Head of Clinical Research Bureau, 3rd Dpt Internal Medicine and Laboratory, Medical School, National and Kapodistrian University of Athens, “Sotiria” Hospital, Athens, Greece
Chatzara E.
Medical Oncologist, University Hospital of Larissa, Greece
Cholis N.
Medical Oncologist, General Hospital of Rhodes, Greece
Chrisoglou S.
MD, MSc, Resident in Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece
Christakou E.
MD, Medical Oncology Resident, Metaxa Memorial Center Hospital, Piraeus
Christodoulopoulos G.
Oncology Resident, University Hospital of Larissa, Greece
Drizou M.
Medical Oncologist - Consultant, Chios General Hospital, Chios, Greece
Eleftherakis-Papaiakovou E.
Medical Oncologist, MD, MSc, PhD, Consultant, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Evangelou G.
MD, MSc, PhD, Medical Oncologist, 3rd Department of Medicine, NKUA, Sotiria Hospital, Athens, Greece
Fergadis E. G.
Medical Oncologist, Consultant, “Metaxa” Hospital, Piraeus, Greece
Galani Ε.
MD, PhD, Consultant Medical Oncologist, 2nd Oncology Department, Metropolitan Hospital, Athens, Greece
Gazouli I.
Medical Oncologist, 1st Oncology Department, Metropolitan Hospital, Athens, Greece
Georgoulias V.
Professor Emeritus of Medical Oncology, University of Crete, Heraklion, Greece
Goura S.
MD, PhD, Medical Oncologist, 2nd Oncology Clinic, Metropolitan Hospital, Athens, Greece
Grivas A.
MD, Medical Oncologist Consultant, 2nd department of Medical Oncology, “Agios Savvas” Anticancer Hospital, Athens, Greece
Kalapanida D.
MD, PhD, Medical Oncologist, 3rd Medical Oncology Department, Hygeia Hospital, Athens
Karkaletsos G.
MD, MSc, Medical Oncologist, Metropolitan Hospital, Athens, Greece
Katsaounis P.
MD, MSc, Medical Oncologist, Metropolitan General Hospital, Athens, Greece
Kokkali S.
MD, MSc, Consultant Medical Oncologist, General Hospital of Athens Hippocratio, Athens, Greece
Kokkalis A.
Resident In Medical Oncology, MSc, PhD Candidate, Univ ersity Hospital of Lar issa, Greece
Kontopodis Ε.
MD, Medical Oncologist, Venizeleion General Hospital of Heraklion, Crete, Greece
Kosmas Ch.
MD, Consultant & Head: Department of Medical Oncology & Hematopoietic Cell Transplant Unit, “Metaxa” Cancer Hospital, Piraeus, Greece
Kotsakis Α.
MD, PhD, Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larissa, Thessaly, Greece
Kotteas Ε.
Associate Professor of Oncology, National & Kapodistrian University of Athens
Koumarianou A.
MD, PhD in Tumor Immunotherapies, Imperial College, Consultant in Medical Oncology, Fourth Department of Internal Medicine, Attikon University Hospital, Athens, Greece
Koutras Α.
Associate Professor of Medical Oncology, Medical School, University of Patras, Head of the Division of Oncology, Department of Medicine, University Hospital of Patras, Greece
Labropoulos S.
Assistant Director, 3rd Medical Oncology Department, Hygeia Hospital, Athens
Lachanas V.
Otorhinolaryngologist - Head & Neck Surgeon, MD, PhD at University Hospital of Larissa, Greece
Laskarakis A.
Professor, Head of the Nursing Department, International Hellenic University, Thessaloniki, Greece
Lavdaniti M.
Professor - Nursing Department, International Hellenic University, Thessaloniki
Lazarou A.
MD, Msc, Resident Doctor, Department of Oncology, University Hospital of Larissa, Greece
Lianos E.
MD, Medical Oncologist, Sr Consultant, Med Oncology Dpt., METAXA Memorial Cancer Center Hospital, Piraeus, Greece
Liontos M.
Medical Oncologist, Assistant Professor Dept of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Machairas N.
MD, PhD, FACS, Assistant Professor of Surgery, 2nd Department of Propaedeutic Surgery, General Hospital Laiko, National and Kapodistrian University of Athens, Athens, Greece
Markou Α.
MD, Medical Oncologist, University Hospital of Larissa, Greece
Nikolaidi A.
Medical Oncologist, Deputy Director Oncology Department, MITERA Hospital, Athens, Greece
Nikolaou Μ.
MD, MSc, PhD, Medical Oncologist, Anti - Cancer Hospital Agios Savvas, Athens, Greece
Ntola Ch.
RN, Bsc, Msc, Oncology Nurse in Euroclinic Athens Hospital, Athens
Oikonomopoulos G.
Consultant in Medical Oncology, MSc, 2nd Oncology Department, Metropolitan Hospital, N. Faliro, Greece
Panopoulos C.
MD, PhD, Director, Oncology Department, “Euroclinic, Athens, Greece
Pantazopoulos A.
Medical Oncologist, 2nd Propaedeutic Internal Medicine Clinic & Research Unit - Oncology Unit, “Attikon” University General Hospital, Athens, Greece
Papadimitriou C.
Professor of Medical Oncology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian Univerity of Athens, Athens, Greece
Papageorgiou D.
Assistant Professor University of Peloponnese, Head Nurse Oncology Unit Euroclinic Athens, President of Hellenic Oncology Nursing Society, Athens, Greece
Papakostas P.
MD, PhD, Medical Oncologist, Director of 2nd Oncology Clinic, Metropolitan General Hospital, Athens, Greece
Papaxoinis G.
MD, PhD, Consultant Medical Oncologist, Agios Savvas Anticancer Hospital, Athens, Greece
Psyrri A.
Professor of Medical Oncology, Chairman of Internal Medicine and Chief of Medical Oncology, Attikon University Hospital, Athens, Greece
Rapti K.
MD, MSc, Consultant Medical Oncologist, 251 General Airforces Hospital, Athens, Greece
Rigakos G.
MD, MSc, Medical Oncologist, 3rd Oncology Department Contemporary Oncology Team, Hygeia Hospital, Athens, Greece
Rovithi M.
Medical Oncologist, General Hospital of Agios Nikolaos, Crete, Greece
Saloustros E.
MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, General University Hospital of Larissa, Larissa, Greece
Samaras I.
MD, Medical Oncologist, University Hospital of Larissa, Greece
Sotiropoulos G.
MD, PhD, FACS, FEBS (HPB Surgery, Transplantation), Professor of Surgery and Transplantation, National and Kapodistrian University of Athens, Medical School, Director and Chairman, Department of Liver Transplantation and Hepatobiliary Surgery, “Laiko” University Hospital of Athens, Greece
Stribakos A.
Medical Oncologist, Director of 5th Internal Medicine - Oncology Clinic, Hygeia Hospital, Athens, Greece
Tegos Th.
MD, PhD, Medical Oncologist, Evangelismos General Hospital, Athens, Greece
Theochari M.
Medical Oncologist, First Department of Medicine, Laiko General Hospital, Athens, Greece
Tsiatas M.
MD, PhD, BSc (Biol), Director Medical Oncologist, Department o f Medical Oncology and Clinical Trials Unit, Athens Medical Center
Tsoukalas N.
MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Director, Oncology Department, Veterans Hospital (417 NIMTS), Consultant, Henry Dunant Hospital Center, Athens Greece
Tzovaras A.
Medical Oncologist Consultant, Agios Savvas Anticancer Hospital, Athens
Ziogas D.
MD, PhD, Academic Scholar in Medical Oncology, 1st Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details
Sponsors